Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

被引：83

作者：

Saiman, L

Chen, YH

San Gabriel, P

Knirsch, C

机构：

[1] Columbia Univ, Dept Pediat, New York, NY 10032 USA

[2] Pfizer Pharmaceut Inc, New York, NY USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 04期

关键词：

D O I：

10.1128/AAC.46.4.1105-1107.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes)xylosoxidans strains, respectively.

引用

收藏

页码：1105 / 1107

页数：3

相关论文

共 23 条

[1] Microbiology of sputum from patients at cystic fibrosis centers in the United States [J].

Burns, JL ;

Emerson, J ;

Stapp, JR ;

Yim, DL ;

Krzewinski, J ;

Louden, L ;

Ramsey, BW ;

Clausen, CR .

CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :158-163

[2] EFFECT ON PSEUDOMONAS-AERUGINOSA ALGINATE EXPRESSION OF DIRECT PLATING AND CULTURE OF FRESH CYSTIC-FIBROSIS SPUTUM ON TO PSEUDOMONAS ISOLATION AGAR CONTAINING SUBINHIBITORY CONCENTRATIONS OF ROXITHROMYCIN AND RIFAMPICIN [J].

DUPONT, MJ ;

LAPOINTE, JR .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (01) :231-236

[3] THE CHANGING EPIDEMIOLOGY OF CYSTIC-FIBROSIS [J].

FITZSIMMONS, SC .

JOURNAL OF PEDIATRICS, 1993, 122 (01) :1-9

[4] MICROBIOLOGY OF AIRWAY DISEASE IN PATIENTS WITH CYSTIC-FIBROSIS [J].

GILLIGAN, PH .

CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (01) :35-51

[5] MUCOID PSEUDOMONAS-AERUGINOSA IS A MARKER OF POOR SURVIVAL IN CYSTIC-FIBROSIS [J].

HENRY, RL ;

MELLIS, CM ;

PETROVIC, L .

PEDIATRIC PULMONOLOGY, 1992, 12 (03) :158-161

[6] ERYTHROMYCIN REDUCES NEUTROPHILS AND NEUTROPHIL-DERIVED ELASTOLYTIC-LIKE ACTIVITY IN THE LOWER RESPIRATORY-TRACT OF BRONCHIOLITIS PATIENTS [J].

ICHIKAWA, Y ;

NINOMIYA, H ;

KOGA, H ;

TANAKA, M ;

KINOSHITA, M ;

TOKUNAGA, N ;

YANO, T ;

OIZUMI, K .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (01) :196-203

[7]

ICHIMIYA T, 1994, J ANTIMICROB CHEMOTH, V34, P331

[8] Long-term azithromycin may improve lung function in children with cystic fibrosis [J].

Jaffé, A ;

Francis, J ;

Rosenthal, M ;

Bush, A .

LANCET, 1998, 351 (9100) :420-420

[9] Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides [J].

Kobayashi, H .

AMERICAN JOURNAL OF MEDICINE, 1995, 99 :S26-S30

[10]

Kondoh K, 1996, ACTA OTO-LARYNGOL, P56